Heart Test Laboratories (HeartSciences) and Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) have finalised licence agreements for the development and commercialisation of artificial intelligence (AI) algorithms and assets for electrocardiography (ECG).

The licences make Icahn Mount Sinai a shareholder in HeartSciences.

Icahn Mount Sinai’s licences provide the right to use various patented and unpatented AI-powered ECG/EKG algorithms and technologies to screen and diagnose cardiovascular disease.

The licences will allow HeartSciences to access a collection of AI-driven ECG algorithms.

HeartSciences aims to offer these algorithms using a cloud-based, hardware-agnostic platform, thereby enabling it to accept ECGs from several existing ECG devices across the globe, including its MyoVista device.

A database of ECG records was used to develop the algorithms.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The AI cardiovascular algorithms are said to be based on technology developed by faculty from Icahn Mount Sinai, licensed to HeartSciences by Mount Sinai.

HeartSciences CEO Andrew Simpson said: “We continue to advance initiatives that fundamentally transform and de-risk HeartSciences. The closing of our licences with Icahn Mount Sinai now propels us forward with our cardiovascular disease AI-ECG development programmes.

“Combined with the recent creation of a new FDA product classification for AI-ECG algorithms that we believe paves the way for a more structured and quicker 510(k) process of our technologies, we have clear focus on our target milestones.”